REVIEW OF CLINICAL USE OF MONOCLONAL ANTIBODIES (BEVACIZUMAB)
Novia Fahrina Purnama Sari*, Made Dwike Swari Santi, Cece Furwanti, Anggara Martha Pratama and Farida Ulfa
Abstract
Bevacizumab is a humanized monoclonal antibody that has several
potentials as a single agent or in combination with a chemotherapeutic
agent. The first used in metastatic colorectal cancer (mCRC) therapy,
metastatic breast cancer (mBC) therapy, and non-small cell lung cancer
(NSCLC) therapy. Furthermore, there is evidence of clinical use for
antiangiogenic therapy, as assessed by endothelial cell proliferation
and tubule formation and widely accepted as first-line therapy in
combination with chemotherapy. Due to the clinical validation of
bevacizumab as a specific inhibitor of the interaction between VEGFA
and VEGFR2, the increasing number of monoclonal antibodies in
development has targeted VEGFR2 as a promising molecular target for anti-angiogenesis.
Keywords: Bevacizumab, monoclonal antibodies, VEGF-A, VEGFR2, and angiogenesis.
[Full Text Article]